Edition:
United Kingdom

Incyte Corp (INCY.OQ)

INCY.OQ on NASDAQ Stock Exchange Global Select Market

97.11USD
4:13pm GMT
Change (% chg)

$-0.99 (-1.01%)
Prev Close
$98.10
Open
$98.82
Day's High
$99.46
Day's Low
$97.05
Volume
80,017
Avg. Vol
552,060
52-wk High
$153.14
52-wk Low
$92.93

Latest Key Developments (Source: Significant Developments)

Immunovaccine announces positive clinical data from its collaborative combination immunotherapy trial in advanced ovarian cancer
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Immunovaccine Inc ::IMMUNOVACCINE ANNOUNCES POSITIVE CLINICAL DATA FROM ITS COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL IN ADVANCED OVARIAN CANCER.IMMUNOVACCINE INC - ‍DATA FROM FIRST DOSING COHORT FROM COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL​ SHOW A 70% DISEASE CONTROL RATE DATA.IMMUNOVACCINE - EXPECTS TO PROVIDE CLINICAL UPDATE ON SECOND DOSING COHORT OF DPX-SURVIVAC IN FIRST HALF OF 2018.IMMUNOVACCINE - ‍DATA FROM FIRST DOSING COHORT FROM COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL FOR DPX-SURVIVAC​DEMONSTRATE TOLERABLE SAFETY PROFILE.  Full Article

Incyte initiates clinical trial of Ruxolitinib for treatment of essential thrombocythemia
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Incyte Corp :Incyte announces initiation of pivotal clinical trial of Ruxolitinib (Jakafi®) for the treatment of essential thrombocythemia.Incyte Corp - ‍announced that first patient has been treated in reset pivotal trial evaluating Ruxolitinib​.  Full Article

Incyte says Q3 earnings per share $0.17
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Incyte Corp -:Incyte reports 2017 third-quarter financial results and updates on key clinical programs.Q3 revenue $382 million versus I/B/E/S view $360.2 million.Q3 earnings per share $0.17.Q3 earnings per share view $0.07 -- Thomson Reuters I/B/E/S.Incyte Corp- for the quarter ended September 30, 2017, total revenues were $382 million as compared to $269 million for the same period in 2016.Incyte Corp - co updated FY 2017 financial guidance‍​.Incyte Corp now sees FY 2017 Jakafi net product revenues in a range of $1,125 million to $1,135 million versus prior view of $1,090 million to $1,120 mln‍​.Incyte Corp - reaffirms Iclusig net product revenues FY 2017 guidance.  Full Article

Incyte and AstraZeneca to enter clinical trial collaboration in early lung cancer
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Incyte Corp :Incyte and AstraZeneca to enter clinical trial collaboration in early lung cancer.Incyte - ‍phase 3 trial evaluating Imfinzi and epacadostat in patients with unresectable non-small cell lung cancer is expected to begin in first-half 2018​.  Full Article

Incyte and MacroGenics announce global collaboration and licensing agreement
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Incyte Corp :Incyte and MacroGenics announce global collaboration and licensing agreement for Anti-PD-1 Monoclonal Antibody MGA012.MacroGenics inc - ‍Incyte gains exclusive, worldwide development and commercialization rights to MGA012 in all indications​.MacroGenics Inc - ‍upon closing, Incyte will pay MacroGenics an upfront payment of $150 million​.MacroGenics - ‍co is eligible to receive up to $420 million in potential development, regulatory milestones, up to $330 million in potential commercial milestones​.MacroGenics Inc - ‍MacroGenics retains right to manufacture a portion of both companies' global clinical and commercial supply needs of MGA012​.MacroGenics Inc - ‍MacroGenics intends to utilize its commercial-scale GMP facility, which is expected to be fully operational in 2018​.MacroGenics - ‍if MGA012 approved & commercialized, co will be eligible to get royalties, tiered from 15 percent to 24 percent, on future sales by Incyte​.  Full Article

Concert Pharma Says PTAB denies Incyte petition challenging CTP-543 patent
Thursday, 19 Oct 2017 

Oct 19 (Reuters) - Concert Pharmaceuticals Inc ::Concert Pharma says patent trials and appeal board of u.s. patent and trademark office has denied Incyte's petition to institute IPR​.  Full Article

European Commission approves once-daily olumiant tablets for treatment of rheumatoid arthritis
Monday, 13 Feb 2017 

Incyte Corp : European Commission approves once-daily olumiant tablets for treatment of adults with moderate-to-severe active rheumatoid arthritis . Incyte -as a result of approval of olumiant by European Commission, Incyte becomes eligible to receive a milestone payment of $65 million from Lilly .Incyte Corp - Phase 3 trial for patients with psoriatic arthritis is expected to be initiated in 2017.  Full Article

Incyte reported Q2 EPS $0.18
Tuesday, 9 Aug 2016 

Incyte Corp : Quarter financial results and updates key clinical programs . Q2 earnings per share $0.18 . Q2 earnings per share view $-0.02 -- Thomson Reuters I/B/E/S . Q2 revenue $246 million versus I/B/E/S view $234.5 million .Sees 2016 Jakafi net product revenue $825 mln - $835 million.  Full Article

Agenus Inc starts phase 1/2 clinical trial of anti-GITR agonist antibody
Wednesday, 22 Jun 2016 

Agenus Inc : Expect to initiate additional clinical studies with antibodies and immuno-oncology leads from comprehensive pipeline in next twelve months .Agenus announces commencement of phase 1/2 clinical trial of anti-GITR checkpoint antibody INCAGN1876 in patients with solid tumors.  Full Article

Incyte announces phase 3 data of Jakafi study
Friday, 10 Jun 2016 

Incyte Corp : Says announced new 28-week data from phase 3 response-2 study of Jakafi . Says data show that Jakafi was superior to best available therapy in maintaining hematocrit control . Says safety profile of Jakafi was consistent with previous studies . Study shows that nearly five times more patients with pv achieved complete hematologic remission with Jakafi compared to bat at 28 weeks . Says overall, Jakafi was well tolerated . Says findings from this study are consistent with data from response pivotal trial .New phase 3 data show Jakafi (ruxolitinib) is superior to best available therapy in patients with polycythemia vera.  Full Article

REFILE-FACTBOX-Corporate alternative minimum tax threat hits pharma, tech

(Refiles to fix spelling of FACTBOX in headline) Dec 6 The tax overhaul legislation passed by the U.S. Senate jettisoned a long-held Republican goal of repealing the corporate alternative minimum tax (AMT), a move seen as hurting companies that invest heavily in research and development. The Senate's inclusion of the AMT puts the bill, passed narrowly last Saturday, on a collision course with Republicans in the House of Representatives, whose version would repeal the corpora